Soluble ST2 and Cardiovascular Outcome

Recruiting

• Conditions: Cardiovascular Disease

• Registration Number: NCT04460131
• Lead Sponsor: Nanjing Medical University

Brief Summary

Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant cardiovascular morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2) is biomarker of myocardial remodeling and fibrosis; however, little is known regarding their potential association with cardiovascular events. This study aimed to investigate the release of sST2 and its association with cardiovascular events undergoing cardiac surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-01
• Study First Submitted: 2020-07-02
• Study First Submitted QC: 2020-07-02
• Study First Posted: 2020-07-07
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-15
• Last Update Posted: 2022-04-25
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• age ≥ 18 years
• Congenital heart disease requiring surgery
• Valvular heart disease requiring surgery
• Arrhythmia requiring surgery
• Aortic dissection requiring surgery
• Coronary heart disease requiring surgery

Exclusion Criteria

• age <18 years
• pregnancy
• severe renal dysfunction (creatinine >200µmol/L)
• not capable of understanding or signing informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality	30 days after surgery	Number of participants death of 30 days after surgery

Secondary Outcome Measures

Name	Time	Method
Heart failure	30 days after surgery	requiring initiation or change in heart failure medication or requiring hospitalisation

Trial Locations

Locations (1)

The first affiliated hospital of nanjing medical university; 🇨🇳 Nanjing, Jiangsu, China